The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

This is a randomized, double‐blind, placebo‐ controlled phaseⅠb/Ⅱclinical study. Totally 108 subjects are planned to enrolled with 36 subjects in three low‐dose groups (group 1, group 2 and group 3) and 72 subjects in three high‐dose groups (group 4, group 5, and group 6).12 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each low‐dose group, randomly given SHR‐1209 or placebo treatment at a ratio of 5:1. 24 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each high‐dose group, randomly given SHR‐1209 or placebo treatment at a ratio of 5:1. The primary objective of this study is to evaluate the safety, tolerability, and efficacy of multiple subcutaneous injections of SHR‐1209 in hyperlipidemia subjects treated with stabilized dose of statin. Groups detail as follows: 1. SHR‐1209 dose 1 /placebo frequence 1 2. SHR‐1209 dose 2 /placebo frequence 2 3. SHR‐1209 dose 3 /placebo frequence 3 4. SHR‐1209 dose 4 /placebo frequence 1 5. SHR‐1209 dose 5 /placebo frequence 2 6. SHR‐1209 dose 6 /placebo frequence 3